The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors

Objective: Refractory or recurrent pediatric solid tumors lack effective treatments, and are associated with dismal outcomes. Hence, there is an urgent need for a novel therapeutic strategy. This study aimed to evaluate the efficacy and safety of anlotinib, a novel oral multi-kinase angiogenesis inh...

Full description

Bibliographic Details
Main Authors: Suying Lu, Ye Hong, Huimou Chen, Liuhong Wu, Feifei Sun, Juan Wang, Jia Zhu, Yi Que, Lian Zhang, Zijun Zhen, Xiaofei Sun, Junting Huang, Yizhuo Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
anlotinib
refractory or recurrent
pediatric
solid tumors
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.711704/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.711704/full

Similar Items